GlaxoSmithKline to sell Lucozade in China

Drug multinational GlaxoSmithKline said it would sell, Lucozade, the energy drink, in the Chinese supermarkets, a move signifying drug-maker's effort to push itself into the emerging markets of the world.

GlaxoSmithKline has penned a deal with President Trading to distribute it through out China.

Lucozade was first invented by a Newcastle chemist in 1927 to provide ailing children a glucose boost.

Lucozade, which is mainly sold in Britain, Hong Kong and Ireland, generates around 400 million pounds in sales annually.

It was also informed that Glaxo also struck an agreement worth €1.5 billion to sell its pneumonia as well as meningitis vaccines in Brazil.

Speaking on the topic, analyst Damian McNeela, said, "What we're seeing out of Glaxo is the willingness to do more deals in more territories to expand distribution and increase revenues, and in particular in emerging markets."

The drug-maker is also pursuing discussions to sell Lucozade in other countries such as Germany and Indonesia.